Mobile

A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subj...

Update Il y a 4 ans
Reference: EUCTR2006-003366-33

A phase II, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability and efficacy study of add-on Cladribine tablet therapy with Rebif New Formulation in Multiple Scleroris Subjects with Active Disease

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Evaluate the safety and tolerability of oral cladribine (cladribine tablets)when added on to Rebif. Evaluate the efficacy of oral cladribine (cladribine tablets) when added on to Rebif compared to placebo when added on to Rebif in MS subjects with active disease

Inclusion criteria

  • Multiple sclerosis

Links